Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induce
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
(Date:6/30/2015)... WA (PRWEB) , ... June 30, 2015 , ... ... a hydrophilic filter that does not sacrifice selectivity to achieve faster flow rates ... combines extremely fine pores with significant open space to allow easy liquid flow ...
Breaking Biology Technology:UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... run. Like a thief across a neighbor's yard. Take the money and ... run. Cause you found out that it wasn't hard to take the ... words and music by Graham Nash , 1975. , ,It ... top spot - sent packing with a tractor trailer load of severance ...
... interconnected vision for the University of Wisconsin System , ... technology. , , Meachen Meachen, associate vice president ... students at the University of Wisconsin-Superior someday signing ... university, UW-Madison . , ,And why not? Through the ...
... Wis. - Higher operating expenses offset strong quarterly revenue ... rich media communications technology, reported a net loss of $1.4 ... of fiscal year 2007. , ,The quarterly net loss ... per share net loss in the same quarter of 2006. ...
Cached Biology Technology:CEOs Gone Wild? Risks and rewards in the executive suite 2CEOs Gone Wild? Risks and rewards in the executive suite 3CEOs Gone Wild? Risks and rewards in the executive suite 4CEOs Gone Wild? Risks and rewards in the executive suite 5CEOs Gone Wild? Risks and rewards in the executive suite 6CIO Leadership Series: Ed Meachen, University of Wisconsin System 2CIO Leadership Series: Ed Meachen, University of Wisconsin System 3CIO Leadership Series: Ed Meachen, University of Wisconsin System 4CIO Leadership Series: Ed Meachen, University of Wisconsin System 5
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/24/2015)... June 24, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... are primary producers of ammonia in Houston,s atmosphere, and cars ... according to a new study by researchers at Rice University ... air quality draws minimal oversight from the Environmental Protection Agency ... it means to life in and around the metropolis. ...
... N.Y. DNA and protein sequencing have forever ... of these complex biomolecules has revolutionized drug development, ... evolution and development. But, one major molecule in ... biopolymers. Today, for the first time ...
... A tiny piece of a critical receptor that fuels the ... discovered by University at Buffalo scientists as a promising new ... on the NMDA (N-methyl-D-aspartate) receptor is being published online Oct. ... time that this site has been shown to be useful ...
Cached Biology News:Ammonia gets overdue overview 2Ammonia gets overdue overview 3Uncharted territory: Scientists sequence the first carbohydrate biopolymer 2Uncharted territory: Scientists sequence the first carbohydrate biopolymer 3New drug target for Alzheimer's, stroke is discovered by University at Buffalo scientists 2
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... Polymerase I from E. coli ... The enzyme also contains both ... 5'?3' exonuclease activity enables the ... gaps in the DNA as ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... Description: Topoisomerase I relaxes both positively and negatively ... of phosphodiester bonds (1,2) . Relaxing supercoiled DNA ... by a single nucleotide pair by gel electrophoresis ... absence of Mn 2+ and can be ...
Biology Products: